No way! But... [Design Issues]

posted by wienui  – Germany/Oman, 2019-12-07 05:01 (2019 d 04:35 ago) – Posting: # 20955
Views: 9,566

(edited on 2019-12-07 06:47)

Dear all,

❝ So here two answers - theoretically there is no problem to use all data, but regulatory authorities can bann you for it. (IMHO)


I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?

Best regards,
Osama

Cheers,
Osama

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
30 visitors (0 registered, 30 guests [including 19 identified bots]).
Forum time: 10:36 CEST (Europe/Vienna)

In matters of style, swim with the current;
in matters of principle, stand like a rock.    Thomas Jefferson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5